| Eli Berk joined KBL in 2000. Mr. Berk is active in the sourcing, evaluating, structuring and monitoring of KBL's investments. Mr. Berk was instrumental in KBL's investments in Achillion Pharmaceuticals, CardioFocus and Magellan Biosciences.
Previously, Mr. Berk served in a variety of financial management roles at AIG International and Seaport Securities where he focused on investments in biotechnology and medical device companies. He currently serves as a board observer with CardioFocus, Prolong Pharmaceuticals and Magellan Biosciences.
Mr. Berk earned a B.A. degree in Political Science from Fordham University and an M.B.A. from Columbia Business School. |
